摘要
目的初步探讨人血管内皮抑制肽在小鼠/裸鼠移植瘤术后残瘤模型中的抗癌药效学作用。方法建立S180肉瘤昆明小鼠手术后残瘤和人结肠癌Lovo裸鼠手术后残瘤模型,评价人血管内皮抑制肽对小鼠手术后残瘤的抑制效应,选择恩度(重组人血管内皮抑素)作为阳性对照药。结果人血管内皮抑制肽给药组对S180肉瘤昆明小鼠手术后残瘤生长产生较强的抑制作用,按照肿瘤体积得出的抑制率范围为16.9%～43.9%,按照瘤重得出的抑制率范围为21.2%～45.5%;人血管内皮抑制肽给药组对人结肠癌Lovo裸鼠手术后残瘤生长产生较强的抑制作用,按照肿瘤体积得出的抑制率范围为42.0%～70.3%,按照瘤重得出的抑制率范围为45.5%～73.8%。结论人血管内皮抑制肽对小鼠/裸鼠手术后残瘤的生长具有较强的抑制作用,为人血管内皮抑制肽开发和临床应用奠定了基础。
OBJECTIVE To preliminarily study the pharmacodynamic effects of human endostatin peptide in murine model of sur- gery residual tumors. METHODS A mice model of S180 sarcoma surgery residual tumor and a nude mice model of human Lovo colon cancer surgery residual tumor were established. Recombinant endostatin （endostar） was selected as the positive control. The inhibitory effect of human endostatin peptide on surgery residual tumors in mice was preliminarily studied. RESULTS The growth of surgery re- sidual tumor of S180 sarcoma in mice were inhibited by human endostatin peptide. The inhibition rates reached 16. 9% -43.9% ac- cording to tumor volume, in accordance with the inhibition rates of tumor weight of 21.2% -45.5%. In nude mice model of human Lovo colon cancer surgery residual tumor, endostatin peptide produced strong inhibitory effect with tumor volume inhibition rates of 42. 0% -70. 3% and tumor suppression rates of 45.5% -73.8%. CONCLUSION Human endostatin peptide has inhibitory effect on surgery residual tumors in mice, and may have the potential for development and clinical application.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2011年第22期1715-1718,共4页
Chinese Pharmaceutical Journal
基金
国家"重大新药创制"科技重大专项(2009ZX09103-659)
关键词
人血管内皮抑制肽
RGD肽
术后残瘤
血管生成
抗癌治疗
human endostatin peptide
RGD peptide
Post-surgical Residual tumor
angiogenesis
anticancer therapy
